8-K: Milestone Scientific CEO Arjan Haverhals to Retire, Neal Goldman Appointed Interim CEO

Milestone Scientific's CEO, Arjan Haverhals, will retire at the end of 2024, with Chairman Neal Goldman stepping in as Interim CEO.

Summary

• Milestone Scientific's CEO, Arjan Haverhals, will retire on December 31, 2024, after a 30-year career in the medical device and pharmaceutical industries.
• His retirement is due to personal reasons, not disagreements with the company's management or board.
• Neal Goldman, the Chairman of the Board, will become the Interim CEO effective upon Mr. Haverhals' departure.
• The company will engage an executive search firm to find a permanent CEO.
• Mr. Haverhals will continue to serve as a director and consultant to ensure a smooth transition, receiving $350,000 for consulting services in 2025.
• Mr. Haverhals will receive his 2024 bonus, with 50% in cash and 50% in stock.
• The company has achieved a favorable Medicare Part B Physician payment rate for the CompuFlo Epidural System.

Sentiment

Score: 7

Explanation: The document conveys a positive sentiment regarding the company's future, despite the CEO transition. The smooth transition plan and the positive comments from both the outgoing and incoming leaders contribute to this score.

Positives

• The transition plan includes Mr. Haverhals remaining as a director and consultant, ensuring continuity.
• The company has secured a favorable Medicare Part B Physician payment rate for the CompuFlo Epidural System.
• Neal Goldman brings extensive financial and corporate governance expertise to the Interim CEO role.
• Mr. Haverhals' retirement is not due to any disagreements with the company's management or board.

Negatives

• The company is undergoing a leadership transition, which could create some uncertainty.
• The search for a new CEO will take time and may disrupt operations.

Risks

• The company faces risks related to the implementation of its business plan, revenue growth, and regulatory approvals.
• There are risks associated with general economic conditions, competitive pressures, and changes in customer requirements.
• The company's future success depends on the successful commercialization of the CompuFlo Epidural System.

Future Outlook

The company is committed to finding a CEO to drive the full commercialization of CompuFlo and build upon the foundation laid by Mr. Haverhals.

Management Comments

• We are deeply grateful to Arjan for his tireless dedication and remarkable contributions to Milestone Scientific, stated Neal Goldman, Chairman of Milestone Scientific.
• Under his leadership, the company achieved substantial improvements in both financial and operational stability, laying a solid foundation for future growth.
• It has been an incredible honor to lead Milestone Scientific, and I am immensely proud of what we have accomplished together, noted Mr. Haverhals.
• I am optimistic about the company's growth prospects, especially as the groundwork we've laid enables new opportunities for innovation and expansion, said Mr. Haverhals.

Industry Context

The medical device industry often sees leadership transitions, and this announcement is part of that normal cycle. The focus on commercializing the CompuFlo system aligns with the industry's push for innovative medical technologies.

Comparison to Industry Standards

• Leadership transitions are common in the medical device industry, with companies like Medtronic and Stryker also experiencing CEO changes.
• The appointment of an interim CEO while searching for a permanent replacement is a standard practice in the industry.
• The focus on commercializing a specific product, like the CompuFlo system, is similar to other companies in the sector that are focused on bringing new technologies to market.
• The consulting agreement with the outgoing CEO is a common practice to ensure a smooth transition and maintain institutional knowledge.

Management Changes

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the leadership transition.
• Employees will experience a change in leadership, but the transition plan aims to minimize disruption.
• Customers and suppliers should not be significantly impacted by the leadership change.
• Creditors are unlikely to be affected by this announcement.

Next Steps

• The Board of Directors will engage an independent executive search firm to identify a permanent CEO.
• Mr. Haverhals will work closely with Mr. Goldman to ensure a smooth transition.
• The company will focus on the commercialization of the CompuFlo Epidural System.

Key Dates

Keywords

CEO transition, Milestone Scientific, Arjan Haverhals, Neal Goldman, Interim CEO, CompuFlo Epidural System, Medicare, medical devices, executive search